alpha- amino- 2'- chloro- 5- (phosphonomethyl)(1,1'- biphenyl)- 3- propanoic acid

structure given in first source; RN given refers to (S)-isomer

Also Known As:

SDZ 220-581; SDZ 220-581, (R)-isomer; SDZ-220-581

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        alpha-amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid: 2
- Carboxylic Acids: 973
  - Acyclic Acids
    - Propionates: 988
      - alpha-amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid: 2
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Propionates: 988
      - alpha-amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid: 2

Related Diseases

1.	Seizures (Absence Seizure) 06/01/1996 - "With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. "
2.	Parkinson Disease (Parkinson's Disease) 10/31/1996 - "The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease. " 10/31/1996 - "Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease."
3.	Catalepsy 10/31/1996 - "The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats." 10/31/1996 - "The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease. " 10/31/1996 - "Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease."

Related Drugs and Biologics

1.	Glutamate Receptors (Glutamate Receptor)
2.	N-Methylaspartate (NMDA)
3.	Propionates
4.	Haloperidol (Haldol)
5.	diphenyl (biphenyl)
6.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
7.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
8.	Levodopa (L Dopa)
9.	Dihydroxyphenylalanine (Dopa)